Hyong Kim

CMO Hyong Kim sells 36.0K shares of ALHC at $19.86 for $713.9K under 10b5-1 plan; stock up 25.8% in 30 days.

Hyong Kim, Chief Medical Officer, sold 35,951 shares at $19.86 on 2026-06-12 as part of a pre-arranged 10b5-1 trading plan, reducing holdings by 9.8% to 331,750 shares. The sale occurred after a 30-day gain of 25.8%, though the stock remains -17.1% from its 52-week high of $23.87. His three prior sales at ALHC generated 90-day returns of +19.1%, +23.2%, and +29.6%, while his cross-ticker track record across all open-market activity shows an average 90-day return of +24.0% following sales. The company reported annual revenue growth of 46.1% and $1.2B quarterly revenue, but remained unprofitable on a full-year basis with a P/E of 197.80, reflecting early-stage growth dynamics where the market is pricing in future profitability.

CMO Kim Hyong sold 85,034 shares at blended $17.46 for $1.5M, reducing stake by 19.0%.

Kim Hyong, Chief Medical Officer at Alignment Healthcare, executed 2 separate sales totaling 85,034 shares for $1,484,690.77 ($1.5M) on consecutive days at prices of $17.29 and $17.57, reducing holdings from 447,367 to 362,333 shares. The sales occurred at prices modestly above the current market price of $17.31 and well within the 52-week range of $10.27–$19.78. His prior sale at this ticker on 2024-12-05 produced a 90-day return of +29.6%, indicating the stock rose after that sale; his same-ticker timing record shows 0 of 1 prior sells were well-timed at the 90-day mark. The company posted $1.0B in quarterly revenue with +48.2% annual growth, but was unprofitable over its most recent full fiscal year. The magnitude of the stake reduction (-19.0%) and the consecutive-day structure warrant monitoring for context regarding the timing relative to any material corporate events or strategic windows.

CMO Kim Hyong sold 62,574 shares of ALHC at $12.20 on 2024-12-05, reducing stake by 11.7% to 470,496 shares post-transaction.

Kim Hyong, Chief Medical Officer, executed a 62,574-share sale at $12.20, netting $763,571.75 and reducing his holdings from 533,070 shares to 470,496 shares. The sale occurred at a price 7.1% above the current price of $11.39, and notably the stock has declined 19.5% over the past 30 days and sits 19.5% below its 52-week high of $14.15. Against this backdrop of recent weakness, Hyong's divestiture of 11.7% of his holdings warrants attention given that the company remains unprofitable (net income of $-26,413,000 for the latest quarter despite 27.2% annual revenue growth). The timing and scale of this sale by a senior executive in an unprofitable yet growing healthcare company merits scrutiny, particularly as the stock has materially underperformed recent highs.